Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > some numbers to consider
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(30)
•••
Comment by DanGSstockson Apr 29, 2021 1:59pm
156 Views
Post# 33094521

RE:some numbers to consider

RE:some numbers to considerLet's see if I can add a picture so that the table formating is more legible
BUY MODEL   1 unit service contract        
          USD 50,000 USD 10,000        
year 16,800 Units   x = 151 Units   sale revenue contract revenue total revenue PE multiple MC  
2021 1 x 151 Units sold USD 7,567,568 USD 1,513,514 USD 9,081,081 5 USD 45,405,405  
2022 2 x 303 Units sold USD 15,135,135 USD 1,513,514 USD 16,648,649   USD 83,243,243  
2023 4 x 605 Units sold USD 30,270,270 USD 4,540,541 USD 34,810,811   USD 174,054,054  
2024 8 x 1211 Units sold USD 60,540,541 USD 10,594,595 USD 71,135,135   USD 355,675,676  
2025 16 x 2422 Units sold USD 121,081,081 USD 22,702,703 USD 143,783,784   USD 718,918,919  
2026 16 x 2422 Units sold USD 121,081,081 USD 46,918,919 USD 168,000,000   USD 840,000,000  
2027 16 x 2422 Units sold USD 121,081,081 USD 71,135,135 USD 192,216,216   USD 961,081,081  
2028 16 x 2422 Units sold USD 121,081,081 USD 95,351,351 USD 216,432,432   USD 1,082,162,162  
2029 16 x 2422 Units sold USD 121,081,081 USD 119,567,568 USD 240,648,649   USD 1,203,243,243  
2030 16 x 2422 Units sold USD 121,081,081 USD 143,783,784 USD 264,864,865   USD 1,324,324,324  
2031           USD 168,000,000 USD 168,000,000   USD 840,000,000  
            above numbers include units from previous years, ie coumpounded      
                     
LEASE MODEL   1 unit consumables service contract      
          USD 15,000 USD 40,000 USD 10,000      
year 16,800 Units   x = 151 Units   lease revenue consumable revenue SC revenue total revenue PE multiple MC
2021 1 x 151 Units leased USD 2,270,270 USD 6,054,054 USD 1,513,514 USD 9,837,838 5 USD 49,189,189
2022 2 x 303 Units leased USD 6,810,811 USD 18,162,162 USD 4,540,541 USD 29,513,514   USD 147,567,568
2023 4 x 605 Units leased USD 15,891,892 USD 42,378,378 USD 10,594,595 USD 68,864,865   USD 344,324,324
2024 8 x 1211 Units leased USD 34,054,054 USD 90,810,811 USD 22,702,703 USD 147,567,568   USD 737,837,838
2025 16 x 2422 Units leased USD 70,378,378 USD 187,675,676 USD 46,918,919 USD 304,972,973   USD 1,524,864,865
2026 16 x 2422 Units leased USD 106,702,703 USD 284,540,541 USD 71,135,135 USD 462,378,378   USD 2,311,891,892
2027 16 x 2422 Units leased USD 143,027,027 USD 381,405,405 USD 95,351,351 USD 619,783,784   USD 3,098,918,919
2028 16 x 2422 Units leased USD 179,351,351 USD 478,270,270 USD 119,567,568 USD 777,189,189   USD 3,885,945,946
2029 16 x 2422 Units leased USD 215,675,676 USD 575,135,135 USD 143,783,784 USD 934,594,595   USD 4,672,972,973
2030 16 x 2422 Units leased USD 252,000,000 USD 672,000,000 USD 168,000,000 USD 1,092,000,000   USD 5,460,000,000
2031       Units leased USD 252,000,000 USD 672,000,000 USD 168,000,000 USD 1,092,000,000   USD 5,460,000,000
          above numbers include units from previous years, ie coumpounded      

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities